MetaVia (MTVA) Competitors $1.88 -0.08 (-4.08%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsSEC FilingsTrends MTVA vs. FBLG, PMVP, CLSD, ANIX, UNCY, VHAQ, BGM, CTMX, SLS, and ONCYShould you be buying MetaVia stock or one of its competitors? The main competitors of MetaVia include FibroBiologics (FBLG), PMV Pharmaceuticals (PMVP), Clearside Biomedical (CLSD), Anixa Biosciences (ANIX), Unicycive Therapeutics (UNCY), Viveon Health Acquisition (VHAQ), Qilian International Holding Group (BGM), CytomX Therapeutics (CTMX), SELLAS Life Sciences Group (SLS), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical preparations" industry. MetaVia vs. FibroBiologics PMV Pharmaceuticals Clearside Biomedical Anixa Biosciences Unicycive Therapeutics Viveon Health Acquisition Qilian International Holding Group CytomX Therapeutics SELLAS Life Sciences Group Oncolytics Biotech MetaVia (NASDAQ:MTVA) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership. Do institutionals & insiders believe in MTVA or FBLG? 1.4% of MetaVia shares are held by institutional investors. 1.1% of MetaVia shares are held by company insiders. Comparatively, 20.8% of FibroBiologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community favor MTVA or FBLG? FibroBiologics received 6 more outperform votes than MetaVia when rated by MarketBeat users. CompanyUnderperformOutperformMetaViaOutperform Votes1100.00% Underperform VotesNo VotesFibroBiologicsOutperform Votes7100.00% Underperform VotesNo Votes Is MTVA or FBLG more profitable? FibroBiologics' return on equity of 0.00% beat MetaVia's return on equity.Company Net Margins Return on Equity Return on Assets MetaViaN/A -189.12% -122.31% FibroBiologics N/A N/A -225.34% Does the media refer more to MTVA or FBLG? In the previous week, MetaVia's average media sentiment score of 0.00 equaled FibroBiologics'average media sentiment score. Company Overall Sentiment MetaVia Neutral FibroBiologics Neutral Do analysts rate MTVA or FBLG? MetaVia currently has a consensus price target of $12.00, suggesting a potential upside of 538.30%. FibroBiologics has a consensus price target of $13.00, suggesting a potential upside of 669.23%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts plainly believe FibroBiologics is more favorable than MetaVia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00FibroBiologics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has preferable earnings & valuation, MTVA or FBLG? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetaViaN/AN/A-$12.47MN/AN/AFibroBiologicsN/AN/A-$16.49MN/AN/A SummaryFibroBiologics beats MetaVia on 7 of the 10 factors compared between the two stocks. Get MetaVia News Delivered to You Automatically Sign up to receive the latest news and ratings for MTVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTVA vs. The Competition Export to ExcelMetricMetaViaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.21M$6.55B$5.39B$9.24BDividend YieldN/A2.96%5.37%3.99%P/E RatioN/A9.8989.1117.52Price / SalesN/A334.651,221.8479.25Price / CashN/A64.1243.6036.96Price / Book0.555.105.014.72Net Income-$12.47M$154.66M$117.81M$224.61M7 Day Performance-4.08%1.64%2.03%1.55%1 Month Performance17.50%1.88%4.03%5.12%1 Year PerformanceN/A4.70%26.78%21.25% MetaVia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTVAMetaVia1.6251 of 5 stars$1.88-4.1%$12.00+538.3%N/A$16.21MN/A0.00N/AGap DownFBLGFibroBiologics1.8496 of 5 stars$1.88-6.0%$13.00+591.5%N/A$70.17MN/A0.0010PMVPPMV Pharmaceuticals2.4344 of 5 stars$1.35-2.9%$5.50+307.4%-16.1%$69.86MN/A-1.3550News CoverageCLSDClearside Biomedical3.1154 of 5 stars$0.92-1.0%$5.33+479.7%-28.5%$69.78M$7.70M-2.0430News CoverageGap UpANIXAnixa Biosciences3.4379 of 5 stars$2.13-2.7%$8.50+299.1%-43.3%$68.54M$210,000.00-5.465Analyst ForecastNews CoverageGap UpUNCYUnicycive Therapeutics3.3605 of 5 stars$0.66-3.8%$5.50+733.3%-24.6%$68.51M$680,000.00-0.689Positive NewsVHAQViveon Health AcquisitionN/A$10.00flatN/AN/A$66.49MN/A0.002Gap UpBGMQilian International Holding GroupN/A$9.20-10.9%N/AN/A$66.49M$29.87M0.00298Gap DownTrading HaltedCTMXCytomX Therapeutics4.6308 of 5 stars$0.84-5.2%$5.77+586.4%-46.6%$65.82M$101.21M4.95170SLSSELLAS Life Sciences Group0.1738 of 5 stars$0.93+1.1%N/A+118.4%$65.46M$1M-1.3510Gap DownONCYOncolytics Biotech1.305 of 5 stars$0.81-2.6%$4.00+393.8%-30.9%$64.82MN/A-3.0030News Coverage Related Companies and Tools Related Companies FBLG Alternatives PMVP Alternatives CLSD Alternatives ANIX Alternatives UNCY Alternatives VHAQ Alternatives BGM Alternatives CTMX Alternatives SLS Alternatives ONCY Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MTVA) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredKamala’s final humiliation Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behi...Porter & Company | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MTVA Stock Alerts